Equities Analysts Set Expectations for FENC Q1 Earnings

Adherex Technologies Inc. (NASDAQ:FENC) – Research analysts at HC Wainwright lowered their Q1 2026 earnings per share estimates for shares of Adherex Technologies in a research note issued to investors on Monday, March 30th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.02) for the quarter, down from their previous estimate of $0.07. The consensus estimate for Adherex Technologies’ current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Adherex Technologies’ Q2 2026 earnings at $0.05 EPS, FY2026 earnings at $0.31 EPS, Q1 2027 earnings at $0.17 EPS and Q2 2027 earnings at $0.22 EPS.

Adherex Technologies (NASDAQ:FENC) last issued its quarterly earnings data on Friday, March 27th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.21). The firm had revenue of $13.78 million during the quarter, compared to analyst estimates of $14.75 million. Adherex Technologies had a negative net margin of 22.62% and a negative return on equity of 183.18%.

A number of other research firms have also commented on FENC. Wall Street Zen lowered shares of Adherex Technologies from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 14th. Zacks Research lowered shares of Adherex Technologies from a “hold” rating to a “strong sell” rating in a research report on Wednesday, March 25th. Piper Sandler began coverage on shares of Adherex Technologies in a report on Friday, January 9th. They set an “overweight” rating and a $18.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adherex Technologies in a research report on Thursday, January 22nd. Finally, B. Riley Financial started coverage on Adherex Technologies in a research note on Thursday, February 12th. They issued a “buy” rating and a $16.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Adherex Technologies presently has an average rating of “Moderate Buy” and an average target price of $15.25.

Adherex Technologies Stock Performance

Shares of Adherex Technologies stock opened at $6.42 on Wednesday. The firm has a 50-day moving average of $7.72 and a 200-day moving average of $8.01. Adherex Technologies has a 52-week low of $4.68 and a 52-week high of $9.92. The stock has a market cap of $221.30 million, a PE ratio of -18.88 and a beta of 0.93.

Insiders Place Their Bets

In other Adherex Technologies news, Director Rosty Raykov sold 10,946 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $6.31, for a total transaction of $69,069.26. Following the sale, the director directly owned 113,856 shares in the company, valued at $718,431.36. This represents a 8.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 11.76% of the stock is owned by corporate insiders.

Institutional Trading of Adherex Technologies

An institutional investor recently bought a new position in Adherex Technologies stock. AQR Capital Management LLC acquired a new stake in Adherex Technologies Inc. (NASDAQ:FENC) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 10,897 shares of the company’s stock, valued at approximately $66,000. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Key Adherex Technologies News

Here are the key news stories impacting Adherex Technologies this week:

• Positive Sentiment: HC Wainwright is projecting positive earnings in 2027 (Q1 2027 ~$0.17, Q2 2027 ~$0.22) and raised forward-period estimates that imply recovery after current-year weakness — a bullish signal for longer‑term upside. HC Wainwright estimates / MarketBeat
• Positive Sentiment: Analysts’ consensus recommendation of “Moderate Buy” provides institutional validation and can support buying interest. Consensus Moderate Buy
• Neutral Sentiment: Director Rosty Raykov sold 10,946 shares at an average $6.31 (≈$69k), reducing his stake by 8.77%. The sale was executed under a pre‑arranged Rule 10b5‑1 plan, which typically reduces the informational significance of the trade. SEC Form 4
• Negative Sentiment: HC Wainwright trimmed near‑term and FY2026 forecasts sharply (e.g., FY2026 cut from $0.64 to $0.31; Q1 2026 cut to ($0.02) from $0.07; Q2 2026 cut to $0.05 from $0.14). Reduced near‑term earnings expectations are a clear headwind for the stock. HC Wainwright outlook
• Negative Sentiment: Recent quarterly results showed a miss (last reported EPS -$0.17 vs. est. $0.04; revenue below estimates), leaving the company operating with negative margins and a negative ROE — background weakness that amplifies sensitivity to analyst cuts. Recent results / MarketBeat

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.